StockData
Danaher Corp logo

Danaher Corp (DHR) KPIs and segments

DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 25, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3019% above fair value
$228.58+2.81 (+1.24%)

Close on Nov 18, 2026Market cap $160.81BP/E 37.4Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Danaher · năm tài chính kết thúc December 31 (Fiscal quarters Q1–Q3 end on the Friday nearest the calendar quarter-end; Q3 2026 ended September 25, 2026; FY2025 ended December 31, 2025)

Nhìn nhanh KPI của Danaher: 77 chỉ số vận hành, trong đó có Total Company Core Sales Growth (Non-GAAP), Biotechnology — Core Sales Growth và Life Sciences — Core Sales Growth, lấy từ 132 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Diagnostics($M)6
2,8822,4662,4172,7202,4632,3092,4492,6372,3632,2602,5272,716
Recurring revenue($M)
2,5332,2102,1862,3632,2112,0622,2232,2952,1272,0032,2942,369
North America($M)
1,4391,1321,2651,3101,2281,0641,3181,3231,1571,0421,3371,348
High-growth markets($M)
861811635815721746640768737743685836
Western Europe($M)
474430431484417405400433368380406423
Nonrecurring revenue($M)
349256231357252247226342236257233347
Other developed markets($M)
10893861119794911131019599109
Life Sciences($M)6
1,8651,8791,7372,0851,7921,7771,6802,0321,7821,7701,7451,930
Recurring revenue($M)
1,2821,2681,2031,2781,2161,2141,1361,2611,2281,2081,1921,155
North America($M)
751759689807728762721837796785781806
Nonrecurring revenue($M)
583611534807576563544771554562553775
High-growth markets($M)
571573499621542503458583501495467559
Western Europe($M)
411421408510392394378463365374372424
Other developed markets($M)
132126141147130118123149120116125141
Biotechnology($M)6
1,8071,9201,7972,0331,7981,8501,6121,8691,6531,7131,5241,759
Recurring revenue($M)
1,5841,7221,6421,6831,5901,6941,4571,5491,4221,4781,3091,462
Western Europe($M)
605689726697587708566596587567546568
High-growth markets($M)
594574490591498448439563485458385
North America($M)
550583524639624612543613503607514632
Nonrecurring revenue($M)
223198155350208156155320231235215297
Other developed markets($M)
58745710689826497788179
Recurring revenue($M)
5,3995,2005,0315,3245,0174,9704,8165,1054,7774,6894,7954,986
Nonrecurring revenue($M)
1,1551,0659201,5141,0369669251,4331,0211,0541,0011,419
North America($M)
2,7402,4742,4782,7562,5802,4382,5822,7732,4562,4342,6322,786
High-growth markets($M)
2,0261,9581,6242,0271,7611,6971,5371,9141,7231,6961,5371,854
Western Europe($M)
1,4901,5401,5651,6911,3961,5071,3441,4921,3201,3211,3241,415
Other developed markets($M)
298293284364316294278359299292303350
Diagnostics($M)
614416674713665554718624615556830766
Biotechnology($M)
477556534540352531441508390462325416
Life Sciences($M)
259244225336222-23920137635233235235
Life Sciences($M)
-44-38-27-57-40-41-48-229-52-50-60
Biotechnology($M)
-56-66-64-115-94-80-81-117-117-111-102
Diagnostics($M)
-155-164-144-195-157-125-115-168-129-126-127
Biotechnology($M)
35,50436,00936,69737,33737,29637,56236,12134,60537,421
Diagnostics($M)
25,78525,73114,65714,74814,65314,53714,29114,20414,552
Life Sciences($M)
22,64522,59322,87323,11223,17923,39723,39623,21123,730
Remaining performance obligations (RPO)($M)
7,4007,5005,3004,9004,9004,5004,4004,5004,600
Total Company Core Sales Growth (Non-GAAP)(%)5
3.0%3.0%0.5%2.5%3.0%1.5%0.0%1.0%0.5%-3.5%-4.0%-11.5%
Core Growth ex-Respiratory(%)
5.5%4.5%3.0%4.0%2.5%2.0%1.0%
Contribution / Headwind from Cepheid Respiratory Testing to Total Company Core Sales Growth(%)
2.5%1.5%2.5%1.5%-0.5%0.5%1.0%
Base Business Core Sales Growth (Legacy FY2021Q4–FY2023Q4: Base Business ex-COVID Testing & Vx/Tx)(%)
-4.5%
Currency Exchange Impact(%)
0.0%-1.0%-3.0%-2.5%-1.5%-2.0%1.5%0.5%0.0%1.5%0.5%-1.0%
Reported GAAP Sales Growth(%)
8.5%5.5%3.5%4.5%4.5%3.5%-1.0%2.0%3.0%-3.0%-2.5%-10.0%
Biotechnology — Core Sales Growth (%)(%)2
5.0%2.5%7.0%6.0%6.5%6.0%7.0%8.0%0.0%-7.0%-17.0%-22.5%
Biotechnology — Currency Exchange Impact(%)
0.5%-1.5%-4.5%-3.0%-2.5%-2.0%1.0%1.5%0.5%2.0%1.0%-1.5%
Biotechnology — GAAP Sales Growth(%)
0.5%4.0%11.5%9.0%9.0%8.0%6.0%6.5%-0.5%-9.0%-18.0%-21.0%
Life Sciences — Core Sales Growth (%)(%)2
4.5%5.5%0.5%0.5%-1.0%-2.5%-4.0%1.0%-2.0%-5.5%-3.0%-4.0%
Life Sciences — Currency Exchange Impact(%)
0.5%0.0%-3.0%-2.0%-1.5%-1.5%1.5%0.5%0.5%2.0%1.0%-0.5%
Life Sciences — GAAP Sales Growth(%)
4.0%5.5%3.5%2.5%0.5%0.5%-3.5%5.5%4.5%-1.5%2.0%-1.0%
Diagnostics — Core Sales Growth (%)(%)3
0.5%2.0%-4.0%2.0%3.5%2.0%-1.5%-2.0%5.0%3.0%7.5%-8.5%
Diagnostics — Price Realization (reflecting China VBP centralized procurement)(%)
-1.0%-1.5%-2.0%-1.5%-1.0%-0.5%0.5%
Diagnostics — Currency Exchange Impact(%)
0.0%-1.0%-2.5%-2.0%-1.0%-0.5%1.0%1.0%0.0%1.5%1.0%0.0%
Diagnostics — GAAP Sales Growth(%)
17.0%7.0%-1.5%3.0%4.0%2.0%-3.0%-3.0%5.0%1.5%6.5%-8.5%
Cepheid Respiratory Testing Revenue (GeneXpert 4-in-1 & COVID-19)($M)
350250500500500300650550425300675650
High-Growth Markets % of Total Sales(%)2
31.0%31.0%27.0%29.0%29.0%27.0%30.0%30.0%27.0%
High-Growth Markets YoY Sales Growth(%)
15.0%15.0%6.0%2.0%-2.0%-8.0%-12.0%
Developed Markets YoY Sales Growth(%)
5.0%2.0%3.0%5.0%5.0%-1.0%5.0%-1.0%1.0%
Remaining Performance Obligations / Unfulfilled Backlog($M)2
7,4007,5005,3005,2004,9004,9004,5004,3004,4004,5004,6004,700
RPO Expected within Next 12 Months (%)(%)
41.0%41.0%48.0%47.0%46.0%46.0%48.0%47.0%49.0%52.0%51.0%
RPO Expected in Months 13–24 (%)(%)
26.0%26.0%26.0%26.0%28.0%28.0%26.0%27.0%26.0%25.0%25.0%
Total Contract Liabilities — Current & Noncurrent($M)1
1,7001,7001,7001,6001,6001,7001,7001,5001,6001,6001,8001,700
Revenue Recognized from Prior Contract Liabilities($M)
196267537227204272497200199354547200
Equipment Lease Revenue — OTLs & STLs($M)
147128143123112117114115939599110
Adjusted Operating Profit — Non-GAAP($M)16
1,9001,6981,7951,9341,6881,6181,6991,9321,5941,5701,7441,837
Biotechnology — Adjusted OP($M)
756787768770669759669721608676543643
Life Sciences — Adjusted OP($M)
404395377501376343350524404373401436
Diagnostics — Adjusted OP($M)
831605739750728602766770664604878838
Other / Corporate Unallocated Adjusted Expense($M)
-91-89-89-87-85-86-86-83-82-83-78-80
Adjusted Operating Profit Margin — Non-GAAP(%)
29.0%27.1%30.2%28.3%27.9%27.3%29.6%29.6%27.5%27.3%30.1%28.7%
Biotechnology — Adjusted OP Margin(%)
41.8%41.0%42.7%37.9%37.2%41.0%41.5%38.6%36.8%39.5%35.6%36.6%
Life Sciences — Adjusted OP Margin(%)
21.7%21.0%21.7%24.0%21.0%19.3%20.8%25.8%22.7%21.1%23.0%22.6%
Diagnostics — Adjusted OP Margin(%)
28.8%24.5%30.6%27.6%29.6%26.1%31.3%29.2%28.1%26.7%34.7%30.9%
GAAP Operating Margin(%)
19.0%18.0%22.6%22.0%19.1%12.8%22.2%21.8%16.5%20.3%22.6%20.9%
Biotechnology — Reported GAAP Operating Margin(%)
26.4%29.0%29.7%26.6%19.6%28.7%27.4%27.2%23.6%27.0%21.3%23.6%
Life Sciences — Reported GAAP Operating Margin(%)
13.9%13.0%13.0%16.1%12.4%-13.4%12.0%18.5%2.0%13.2%13.5%12.2%
Diagnostics — Reported GAAP Operating Margin(%)
21.3%16.9%27.9%26.2%27.0%24.0%29.3%23.7%26.0%24.6%32.8%28.2%
Core Operating Margin Change (percentage points)(%)
1.7%-0.1%0.4%-1.2%0.5%0.1%-0.3%1.2%0.5%0.8%-1.7%-5.0%
Biotechnology — YoY Core Operating Margin Change (percentage points)(%)
4.9%0.3%1.4%-0.6%0.8%1.7%7.0%2.9%-1.5%-0.7%-10.7%-6.9%
Life Sciences — YoY Core Operating Margin Change (percentage points)(%)
1.2%2.1%1.0%-1.7%-2.1%-1.6%-2.5%3.8%-0.3%-3.4%-1.7%-2.8%
Diagnostics — YoY Core Operating Margin Change (percentage points)(%)
0.3%-1.7%-0.8%-1.4%1.7%-0.5%-3.4%-1.6%2.1%5.6%4.3%-4.3%
Consolidated Adjusted EBITDA (Non-GAAP Supplemental Data)($M)8
2,1081,8941,9882,1291,8771,8031,8802,1191,7711,7481,9232,015
Biotechnology — Adjusted EBITDA($M)
800827808809707797703759644711585686
Life Sciences — Adjusted EBITDA($M)
452443425549423388395568448414439473
Diagnostics — Adjusted EBITDA($M)
944712841856829702866872759704975935
Other / Corporate — Adjusted EBITDA($M)
-88-88-86-85-82-84-84-80-80-81-76-79
Biên Adjusted EBITDA toàn công ty (Adjusted EBITDA Margin)(%)
32.2%30.2%33.4%31.1%31.0%30.4%32.7%32.4%30.5%30.4%33.2%31.5%
Biotechnology — Biên Adjusted EBITDA(%)
44.3%43.1%45.0%39.8%39.3%43.1%43.6%40.6%39.0%41.5%38.4%39.0%
Life Sciences — Biên Adjusted EBITDA(%)
24.2%23.6%24.5%26.3%23.6%21.8%23.5%28.0%25.1%23.4%25.2%24.5%
Diagnostics — Biên Adjusted EBITDA(%)
32.8%28.9%34.8%31.5%33.7%30.4%35.4%33.1%32.1%31.2%38.6%34.4%
Segment Intangibles Amortization($M)6
513463434428433426410408414402407380
Biotechnology — Intangible Assets Amortization($M)
227231234230231228213213218214218215
Life Sciences — Intangible Assets Amortization($M)
153151152151154150149148147140141116
Diagnostics — Intangible Assets Amortization($M)
1338148474848484749484849
Biotechnology — Intangibles Amortization % of Segment Sales (MD&A)(%)
12.6%12.0%13.0%12.8%12.3%13.2%13.2%12.5%14.3%
Life Sciences — Intangibles Amortization % of Segment Sales (MD&A)(%)
8.2%8.0%8.8%8.6%8.4%8.9%8.2%7.9%8.1%
Diagnostics — Intangibles Amortization % of Segment Sales (MD&A)(%)
4.6%3.3%2.0%1.9%2.1%2.0%2.1%2.1%1.9%
Segment Depreciation($M)7
208196193195189185181187177178179178
Biotechnology — Depreciation($M)
444040393838343836354243
Life Sciences — Depreciation($M)
484848484745454444413837
Diagnostics — Depreciation (including diagnostic instruments placed in hospitals)($M)
113107102106101100100102951009797
Other / Corporate — Depreciation($M)
313232232221
Biotechnology — Depreciation % of Segment Sales (MD&A)(%)
2.4%2.1%2.2%2.1%2.1%2.1%2.2%2.0%2.8%
Life Sciences — Depreciation % of Segment Sales (MD&A)(%)
2.6%2.6%2.8%2.6%2.5%2.7%2.5%2.3%2.2%
Diagnostics — Depreciation % of Segment Sales (MD&A)(%)
3.9%4.3%4.2%4.1%4.3%4.1%4.0%4.4%3.8%
Other Segment Items Under ASU 2023-07 — Total 3 Segments($M)5
4,3504,3913,8944,6144,0944,0493,792
Biotechnology — Other Segment Items($M)
1,0071,0939891,2241,0911,053924
Life Sciences — Other Segment Items($M)
1,4051,4361,3121,5361,3691,3891,285
Diagnostics — Other Segment Items($M)
1,9381,8621,5931,8541,6341,6071,583
Corporate Unallocated Other Items($M)
102888685828484
Total Other Segment Items($M)
4,4524,4793,9804,6994,1764,1333,876
Adjusted Gross Profit Margin — Non-GAAP(%)2
60.6%58.4%60.3%58.2%58.2%59.3%61.4%59.5%58.7%59.7%
GAAP Gross Profit Margin(%)
58.5%57.6%60.3%58.0%58.2%59.3%61.2%59.5%58.7%59.7%
Adjusted Cost of Sales — Non-GAAP($M)
2,5812,6082,3602,8582,5302,4132,2152,6482,3972,315
Adjusted R&D — Non-GAAP($M)1
433412387438378403379442383391
Adjusted R&D % of Sales(%)
6.6%6.6%6.5%6.4%6.2%6.8%6.6%6.8%6.6%6.8%
Adjusted SG&A — Non-GAAP($M)1
1,6401,5471,4091,6081,4571,5021,4481,5161,4241,467
Adjusted SG&A % of Sales(%)
25.0%24.7%23.7%23.5%24.1%25.3%25.2%23.2%24.6%25.5%
Adjusted Net Earnings — Non-GAAP($M)1
1,4941,3751,4631,5861,3491,2921,3561,5561,2461,274
Adjusted Diluted Net Earnings Per Share — Non-GAAP($)
2.111.942.062.231.891.801.882.141.711.72
Free Cash Flow — Non-GAAP($M)3
1,6321,2651,0851,7691,3701,0941,0601,5041,2261,1311,4481,163
FCF to Adjusted Net Earnings Conversion Ratio(×)
1.351.451.051.501.511.971.111.381.501.251.331.04
OCF to GAAP Net Earnings Conversion Ratio(×)
1.561.761.281.791.832.411.361.861.851.561.601.42
Payments for Repurchase of Common Stock($M)
0894002,01001,0788096404,53000
Finished Goods Inventory($M)
1,6761,8131,3601,2871,3731,3831,2721,1451,3531,3521,2961,282
Work in Process Inventory($M)
542537504469526525517465498491509459
Raw Materials Inventory($M)
916910744733775781743720827828840853
Consolidated Amortization of Intangible Assets — XBRL($M)1
513463434428433426410408414402407380
Consolidated Depreciation — XBRL($M)
208196193195189185181187177178179178
Masimo — Non-Invasive Technology Boards & Instruments Shipped
76,80069,30066,00063,10072,20065,10060,50058,60050,40058,500
Masimo — Healthcare Revenue($M)2
404413372371372368343344
Masimo — Direct & Distribution Channel Revenue($M)
365377330339331326311316311
Masimo — OEM Channel Revenue($M)
38.635.641.432.440.742.132.628.228.8
Masimo — Unrecognized Contract Revenue / RPO($M)
1,9521,7941,7141,7201,7621,7731,6521,6021,5081,497
Masimo — Healthcare Gross Profit($M)3
251247231233234168212207
Masimo — R&D Expense($M)
3032.130.529.933.96837.339.1
Masimo — SG&A Expense($M)
143131116139119170137126
Masimo — Operating Income($M)
77.483.983.664.578-70.338.241.9
openFDA — Total FDA 510(k) Medical Device Clearances for the Danaher Ecosystem (Monthly / Quarterly / Annual)8
8481757671178
Beckman Coulter (Diagnostics & Life Sciences) — FDA 510(k) Clearances
104161215853
Cepheid (GeneXpert Molecular Diagnostics) — FDA 510(k) Clearances
302002430102
Radiometer Medical (Blood Gas & Acute Care Analyzers) — FDA 510(k) Clearances
030000110000
Leica Biosystems & Microsystems (Pathology & Microscopy) — FDA 510(k) Clearances
200000000100
HemoCue (Point-of-Care POC Hematology Testing) — FDA 510(k) Clearances
000000000000
Devicor Medical / Mammotome (Breast Biopsy & Cancer Diagnostics) — FDA 510(k) Clearances
002000011010
Masimo Corporation (Pulse Oximetry & Non-Invasive Patient Monitoring) — FDA 510(k) Clearances
210012001113
U.S. Industry Benchmark — U.S. Industry Total 510(k) Clearances
855923756806797886736856767793713877
openFDA — Total FDA PMA (Premarket Approval & Supplements) High-Risk Device Approvals for the Danaher Ecosystem5
010202001010
Beckman Coulter — FDA PMA Approvals
000202001000
Cepheid — FDA PMA Approvals
000000000000
Leica Biosystems — FDA PMA Approvals
010000000010
Masimo Corporation — FDA PMA Approvals
000000000000
U.S. Industry Benchmark — U.S. Industry Total PMA Approvals
565608567525585588524683538550459656
openFDA — Device Recall Events for the Danaher Ecosystem on the FDA Portal8
000000000000
Beckman Coulter (Diagnostics & Life Sciences) — Recall Events on openFDA
000000000000
Cepheid (GeneXpert Molecular Diagnostics) — Recall Events on openFDA
000000000000
Radiometer Medical (Blood Gas & Acute Care Analyzers) — Recall Events on openFDA
000000000000
Leica Biosystems & Microsystems (Pathology & Microscopy) — Recall Events on openFDA
000000000000
HemoCue (Point-of-Care POC Hematology Testing) — Recall Events on openFDA
000000000000
Devicor Medical / Mammotome (Breast Biopsy & Cancer Diagnostics) — Recall Events on openFDA
000000000000
Masimo Corporation (Pulse Oximetry & Non-Invasive Patient Monitoring) — Recall Events on openFDA
000000000000
openFDA — Recall Enforcement Reports for the Danaher Ecosystem
757151713111317775
openFDA — MAUDE Adverse Event Reports for the Danaher Ecosystem7
935467365326284314319268320246269247
Beckman Coulter (Diagnostics & Life Sciences) — MAUDE Adverse Event Reports
541154187174160206205168222143169143
Cepheid (GeneXpert Molecular Diagnostics) — MAUDE Adverse Event Reports
3331378151055107
Radiometer Medical (Blood Gas & Acute Care Analyzers) — MAUDE Adverse Event Reports
253536273637472132171918
Leica Biosystems & Microsystems (Pathology & Microscopy) — MAUDE Adverse Event Reports
102112242022172323162327
HemoCue (Point-of-Care POC Hematology Testing) — MAUDE Adverse Event Reports
000000000010
Devicor Medical / Mammotome (Breast Biopsy & Cancer Diagnostics) — MAUDE Adverse Event Reports
867103514114104
Masimo Corporation (Pulse Oximetry & Non-Invasive Patient Monitoring) — MAUDE Adverse Event Reports
348248120785836214537613748
USAspending.gov — Federal Contract Obligations($M)7
60.432.644.485.839.637.347.999.393.234.134.295.3
Cepheid — U.S. Federal Contracts (GeneXpert test supplies for the VA hospital system & DoD)($M)
11.617.713.432.517.015.218.932.644.03.8816.533.2
Beckman Coulter — U.S. Federal Contracts($M)
8.441.9717.047.33.02-0.0119.552.810.18.5713.545.3
Leica Biosystems & Microsystems — U.S. Federal Contracts($M)
6.722.953.081.702.761.801.612.955.462.112.923.21
SCIEX — U.S. Federal Contracts (mass spectrometry systems for FDA/EPA/NIH/DoD)($M)
8.820.730.530.324.142.360.180.256.615.131.120.46
Cytiva (Global Life Sciences Solutions) — U.S. Federal Contracts (BARDA / HHS / NIH)($M)
0.940.250.050.120.590.480.220.291.160.82-19.80.69
Masimo Corporation — U.S. Federal Contracts($M)
0.030.140.690.330.640.470.300.361.191.220.680.72
Integrated DNA Technologies (IDT) — U.S. Federal Contracts($M)
0.100.200.0200.090.150.020.02-1.08-0.330.15-0.03
Total U.S. Medical & Diagnostic Laboratories Industry Revenue (U.S. Census Bureau QSS — NAICS 6215 Medical & Diagnostic Laboratories)($M)
20,52819,56919,99719,67719,71818,72219,10418,89318,48317,96317,943
Total U.S. Taxable Hospitals Industry Revenue (U.S. Census Bureau QSS — NAICS 622 Hospitals)($M)
47,89646,67446,83446,29545,37045,35845,28443,77843,50543,70943,264
Consolidated Revenue — GAAP($M)13
6,5546,2655,9516,8386,0535,9365,7416,5385,7985,7435,7966,405
Cost of Sales($M)
2,7172,6542,3602,8722,5302,4132,2302,6482,3972,3152,3092,626
Gross Profit($M)
3,8373,6113,5913,9663,5233,5233,5113,8903,4013,4283,4873,779
R&D Expense($M)
433412387438378403379442383391368407
SG&A Expense($M)
2,1592,0721,8602,0261,9912,3601,8582,0232,0601,8691,8072,035
Operating Profit — GAAP($M)
1,2451,1271,3441,5021,1547601,2741,4259581,1681,3121,337
Interest Expense($M)
13510763556771726187656585
Earnings Before Income Taxes($M)
1,1321,0781,2351,3731,0766551,1291,3159771,0831,2711,232
Income Taxes($M)
-75208206190168100175229159176183111
Net Earnings — GAAP($M)
1,2358701,0291,1979085559541,0868189071,0881,079
EPS pha loãng (Diluted Net Earnings Per Share — GAAP)($)
1.751.231.451.270.771.321.121.221.451.45
Basic Net Earnings Per Share — GAAP($)
1.751.231.451.280.771.331.131.231.471.46
Weighted-Average Diluted Shares(M)
707708711714719721729742749
Weighted-Average Basic Shares(M)
704705708711717716723738741
Total Assets($M)9
93,28192,36783,54483,46479,89781,62079,11677,54280,61578,55583,40284,488
Cash and Cash Equivalents($M)
5,6824,3485,7014,6151,5282,9571,9932,0782,6272,3747,0315,864
Accounts Receivable, Net($M)
4,1263,9653,8193,9133,7553,5643,5063,5373,5073,2983,3793,922
Total Inventories($M)
3,1343,2602,6082,4892,6742,6892,5322,3302,6782,6712,6452,594
Property, Plant and Equipment, Net($M)
5,7735,8255,4685,5315,3765,3095,1104,9904,8434,6434,5624,553
Goodwill (increased to $48.887M after Masimo merger)($M)
47,31547,41442,76543,15142,94842,99141,65740,49742,17340,80540,84641,608
Other Intangible Assets, Net (increased to $23.803M after Masimo merger)($M)
21,05221,35817,16617,81718,09718,62918,88518,56819,85419,54519,88820,746
Short-Term Debt & Current Portion of Long-Term Debt (Due Within 1 Year)($M)
2,0941,4119232235025015051,2007011,7461,695
Long-Term Debt($M)
24,38825,14717,56118,41616,83316,85315,97615,50016,32416,30916,41716,707
Total Stockholders' Equity($M)
53,62152,58152,94952,53451,07152,33450,84949,54351,29949,89753,44253,486
Operating Cash Flow — GAAP($M)1
1,8861,5341,3222,1171,6621,3381,2992,0191,5131,4171,7391,619
Capital Expenditures($M)
255269237371292248245516298287291434

59 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Currency unit: Millions of USD (usd_m), except EPS/median compensation in USD (usd), headcount/facilities/permits/units shipped in units (count), shares in millions of shares (millions).
  • Danaher accounting periods: Fiscal year ends 31/12; quarters Q1, Q2, Q3 end on the Friday closest to the calendar quarter-end (Q3 2026 ended 25/09/2026).
  • Calculation rules: The table does not calculate margins, proportions, or growth rates. The only derivation applied is period separation for Q4 = Full Year (10-K) − 9 Months (10-Q Q3) and cash flow derivation from year-to-date figures (YTD − prior YTD). Danaher reports consolidated financial statements under US GAAP and does not issue standalone parent-company statements, so no Consolidated − Standalone deduction is applied.
  • Reporting cycle Q1–Q3 + Full Year: MD&A textual disclosure metrics in 10-Q/10-K (High-Growth Markets revenue share and growth, Diagnostics China VBP pricing impact, depreciation and amortization as a percentage of segment revenue) are only published for Q1, Q2, Q3 (10-Q) and Full Year (10-K); there is no standalone Q4 MD&A report.
  • Restructuring & Acquisitions: (1) On 30/09/2023, Danaher completed the spin-off of the Environmental & Applied Solutions segment into Veralto Corporation (figures from 2022 onward were retrospectively adjusted by the company to continuing operations across 3 segments: Biotechnology, Life Sciences, Diagnostics). (2) On 10/06/2026, Danaher completed the acquisition of 100% of Masimo Corporation ($9.8 billion USD) and consolidated it into the Diagnostics segment; standalone SEC filings for Masimo are presented separately through its final standalone period FY2026Q1.

Không hiện vì thiếu các kỳ gần đây (11)

  • Global Suppliers (>50,000 / >48,000 / >45,000) — Only disclosed as lower-bound estimates (>62,000 in 2022, >50,000 in 2023, >48,000 in 2024, >45,000 in 2025) — excluded.
  • Speak Up! Reports Received and Investigated (>1,000 / >1,220 / >1,200 / >1,300) — Total absolute reports only stated as approximate figures (>1,200, >1,300); retained exact normalized rate of 1.9 reports / 100 associates.
  • Languages Spoken (>20), Associates 18–20 Years Old (<1%), Bonus Participation (>90%) — Only disclosed as approximate figures (>20 languages, <1%, >90%) — excluded.
  • GHG Scope 3 Emissions & Categories 1–15 (3,504,063 tCO2e) — Comprehensive inventory only disclosed for a single year (FY2024 = 3,504,063 tCO2e; FY2023 and FY2025 blank '—'), lacking 2 consecutive years.
  • EEO-1 U.S. Workforce Race/Ethnicity × Gender Matrix (22,953 U.S. associates) — Danaher's website currently publicly hosts only the 2024 EEO-1 report (a single annual period, lacking continuous FY2025/FY2023 data) — excluded.
  • Tariff Refund Impact on Operating Margin (Total Company, %) — occurred in 1 period only, FY2026Q2
  • Tariff Refund Impact on Operating Margin (Biotechnology, %) — occurred in 1 period only, FY2026Q2
  • Tariff Refund Impact on Operating Margin (Life Sciences, %) — occurred in 1 period only, FY2026Q2
  • Tariff Refund Impact (%) — only incurred in 1 period, FY2026Q2
  • Quarterly Price Realization for Total Company, Biotechnology & Life Sciences (Quarterly Price Realization %) — in certain quarters (such as Q1/Q3 2026), the company only qualitatively stated 'did not have a significant impact' in the 10-Q, thus lacking 3 consecutive quarterly data points (retained the FY2022–FY2025 10-K annual series and the Diagnostics quarterly series with complete data points).
  • Diagnostics Core Revenue Growth Excluding Cepheid Respiratory (Diagnostics Core Growth ex-Respiratory %) — only disclosed in Q2 & Q3 2026 earnings calls/presentations (2 quarters), lacking 3 consecutive quarters (retained the Total Company Core Growth ex-Respiratory series with 7 consecutive quarters FY2025Q1–FY2026Q3).

Dữ liệu cập nhật 2026-11-02.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Danaher

See a number that looks wrong?